OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Petrylak on the KEYNOTE-045 Trial for Urothelial Carcinoma

June 9th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancer, discusses the KEYNOTE-045 trial investigating pembrolizumab (Keytruda) versus physician’s choice of chemotherapy for patients with urothelial carcinoma.

Dr. Flinn on 5-Year Follow-up of BRIGHT Study in MCL and iNHL

June 9th 2017

Ian W. Flinn, MD, PhD, director, Blood Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses 5-year follow-up of the BRIGHT study, which explored the combination of bendamustine and rituximab (BR) versus R-CHOP/R-CVP as a first-line treatment for patients with mantle cell lymphoma (MCL) or indolent non-Hodgkin lymphoma (iNHL).

Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

June 9th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

Dr. Arend on Personalized Medicine for Endometrial Cancer

June 9th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses personalized medicine for patients with endometrial cancer.

Dr. Bekaii-Saab on Results of the IDEA Project for Colon Cancer

June 9th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the results of the phase III IDEA project for patients with stage III colon cancer.

Dr. Choueiri on Avelumab Plus Axitinib in mRCC

June 8th 2017

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses phase I results of axitinib (Inlyta) plus avelumab (Bavencio) for the treatment of patients with metastatic renal cell carcinoma (RCC).

Dr. Kelley on the Development of Biomarkers for HCC

June 8th 2017

R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses the development of biomarkers for patients with hepatocellular carcinoma (HCC).

Dr. Rai on the Treatment Paradigm for CLL

June 8th 2017

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the change in the treatment paradigm for chronic lymphocytic leukemia (CLL).

Dr. Shah on Risk Factors for Early-Onset CRC

June 8th 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses risk factors for patients with early-onset colorectal cancer (CRC).

Dr. Grignani on the Future of Treatments for Sarcoma

June 8th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the future of treatments for patients with soft tissue sarcoma.

Dr. Zulueta on the Application of the LuCED Test for Lung Cancer

June 6th 2017

Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.

Dr. Loeb on Tests for the Management of Prostate Cancer

June 6th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses test options to determine the management of patients newly diagnosed with prostate cancer.

Dr. Houber on the De-Escalation of Treatments for Breast Cancer

June 6th 2017

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Dr. Badani on the Future of Robotic Surgery for Kidney Cancer

June 6th 2017

Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the future of robotic surgery for patients with kidney cancer.

The Design Behind the Development of a Novel-Risk Prediction Model in Lung Cancer Screening

June 6th 2017

Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the design of a novel risk-prediction algorithm in the context of screening patients for lung cancer.

Dr. Kaouk on the Results of a Study of Robotic Surgery for RCC

June 6th 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses the results of a study of robot-assisted partial nephrectomy for selected renal mass using an off-clamp approach compared to an on-clamp approach for patients with renal cell carcinoma (RCC).

Dr. Hayes on the Future of Biomarkers for Breast Cancer

June 6th 2017

Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.

Dr. Feldman on the Significance of Active Surveillance in Prostate Cancer

June 6th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses the significance of active surveillance for patients with prostate cancer.

Dr. Rugo on the Significance of the MONARCH I Trial for Breast Cancer

June 2nd 2017

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the significance of the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Dr. Stephenson on 2 Years Following the Management of Localized Prostate Cancer

June 2nd 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the significance of a study investigating urinary, bowel, and sexual function at 2 years following the management of localized prostate cancer.